secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001104659-26-008375
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools completes SomaLogic sale to Illumina for up to $425M; holds ~$550M cash
--------------------------------------------------------------------------------

- Received $350M upfront cash at closing; eligible for up to $75M in earnout payments based on 2025-2026 revenue targets.
- Post-close cash and equivalents estimated at ~$550M, excluding potential earnouts, to fund inorganic growth.
- Retained mass cytometry and microfluidics businesses; continuing operations on track for positive adjusted EBITDA in 2026.
- Company to receive 2% royalty on SOMAmer-based NGS kit sales for 10 years and a co-exclusive license for singleplex assays.
- Transaction marks strategic exit from aptamer/proteomics business; management plans disciplined M&A to accelerate growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000110465926008375/0001104659-26-008375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000110465926008375/tm264472d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-008375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer